Clinical Trials in Optic Nerve Disease Treatment



de

Éditeur :

Springer


Paru le : 2024-07-08



eBook Téléchargement , DRM LCP 🛈 DRM Adobe 🛈
Lecture en ligne (streaming)
158,24

Téléchargement immédiat
Dès validation de votre commande
Ajouter à ma liste d'envies
Image Louise Reader présentation

Louise Reader

Lisez ce titre sur l'application Louise Reader.

Description

This book is a compendium of the worldwide ocular stem cell, gene therapy, and other studies treating Optic Nerve Disease that are registered with Clinicaltrials.gov. The study and the Clinical Trial number is provided in order to make it easier for the reader to obtain further information. The book contains an introduction to Optic Nerve Disease as well as a summary of common optic nerve conditions.
Clinical Trials in Optic Nerve Disease Treatment is a valuable resource for ophthalmologists, optometrists, other physicians, and researchers.
 
Pages
329 pages
Collection
n.c
Parution
2024-07-08
Marque
Springer
EAN papier
9783031588143
EAN PDF
9783031588150

Informations sur l'ebook
Nombre pages copiables
3
Nombre pages imprimables
32
Taille du fichier
10455 Ko
Prix
158,24 €
EAN EPUB
9783031588150

Informations sur l'ebook
Nombre pages copiables
3
Nombre pages imprimables
32
Taille du fichier
338 Ko
Prix
158,24 €

Jeffrey N. Weiss, M.D., is the former Chief of Retinal Surgery at the Joslin Diabetes Center in Boston, Faculty of Harvard Medical School, and Visiting Scientist at the Massachusetts Institute of Technology.


Dr. Weiss is the author of more than 100 publications, including 20 books, holds more than 20 U.S. and foreign patents and has been a Reviewer for multiple scholarly journals. He has served as a Visiting Professor, performed surgery, and lectured both nationally and internationally. Dr. Weiss is also the founder of two companies, Ocular Research Associates Inc., and Micron Ophthalmic, Inc., which have manufactured and sold Dr. Weiss’ inventions worldwide.


Dr. Weiss was the first to invent the equipment and develop the technique to safely perform retinal vessel cannulation. This surgery remains the only option for patients with severe stroke in the eye. He was also the first to report the use of hyperbaric oxygen treatment tosuccessfully treat dry age-related macular degeneration and longer standing central retinal artery occlusions.


Dr. Weiss performed the first retinal stem cell surgery in 2010, and is the Principal Investigator of The Stem Cell Ophthalmology Treatment Studies I/II, the largest retinal and optic nerve stem cell studies in the world, and The Neurologic Stem Cell Treatment Study. The studies are Institutional Review Board (IRB) approved, registered with NIH, and listed on ClinicalTrials.gov.

Suggestions personnalisées